The US market continues to drive growth for Dr Reddy`s and other Indian generic drug companies. What if this paradigm changes in the global context? The US drives the growth but we have to diversify our sources of growth even though the relative importance of the US may not change. Emerging markets
8.53 PM Jun 30th
deal details with the stock exchanges showed. Morgan Stanley Asia Singapore, which is a shareholder of Aurobindo Pharma, sold 17,32,500 shares of the drug company for about Rs 670 apiece, valuing the transaction at Rs 116 crore. Morgan Stanley Asia Singapore held 46.16 lakh shares of Aurobindo Pharma
11.48 AM May 31st
, according to data tracker Dealogic. Many drug companies have paid down debt taken on during a buying spree in the earlier 2000s and are now generating lots of cash they want to put to work. Prescription drug makers are also attracted to acquisitions because deals can allow them cut costs and scale back
4.02 PM Apr 22nd
Source:VC Circle - Sun Pharmaceutical Industries Ltd, the country's top drugmaker by market cap, is acquiring Ranbaxy Laboratories Ltd in an all-stock transaction, creating the world's fifth-largest generics drug company and the largest pharma company in India by far
12.10 PM Apr 8th
I am doctor by profession and knows the value of research and upcoming drugs. COMPANY has spent lot of rs in research and next quarter filing new ADNA / molecules which will drive the earning. you see almost 90% of shares are by institutes or large investor.
12.47 PM Mar 18th
Source:Calcutta Telegraph News - Mumbai, Feb. 20: Cipla has entered into an agreement with MSD to market the latter’s anti-HIV drug raltegravir in the country. This is the first time that Cipla is entering into a strategic partnership with a multinational drug company. MSD is the trade name
2.10 PM Feb 21st
Follow moneycontrol.comFacebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window Windows 8
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.